STERIS (STE) Projected to Release Earnings on Wednesday

STERIS (NYSE:STE) is projected to announce its Q1 2027 results after the market closes on Wednesday, August 5th. Analysts expect STERIS to announce earnings of $2.54 per share and revenue of $1.4957 billion for the quarter. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Interested persons may review the information on the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last announced its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter last year, the business earned $2.74 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, analysts expect STERIS to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

STERIS Trading Up 5.5%

NYSE:STE opened at $230.39 on Wednesday. STERIS has a 12 month low of $195.14 and a 12 month high of $269.44. The firm has a market cap of $22.45 billion, a price-to-earnings ratio of 29.05 and a beta of 0.92. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The company’s 50 day moving average is $212.12 and its 200-day moving average is $226.90.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Investors of record on Monday, June 8th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Monday, June 8th. STERIS’s dividend payout ratio is currently 31.78%.

Insider Activity

In related news, CEO Daniel A. Carestio sold 1,374 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $212.00, for a total transaction of $291,288.00. Following the transaction, the chief executive officer owned 63,647 shares of the company’s stock, valued at approximately $13,493,164. The trade was a 2.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP John Adam Zangerle sold 1,419 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the transaction, the vice president directly owned 35,259 shares in the company, valued at $7,379,003.52. This trade represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 7,328 shares of company stock valued at $1,554,051. 1.12% of the stock is owned by company insiders.

Institutional Trading of STERIS

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. increased its holdings in shares of STERIS by 40.6% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,484 shares of the medical equipment provider’s stock worth $3,165,000 after purchasing an additional 3,607 shares during the period. Compound Planning Inc. acquired a new position in shares of STERIS during the fourth quarter valued at about $220,000. Invesco Ltd. lifted its stake in shares of STERIS by 10.2% in the fourth quarter. Invesco Ltd. now owns 1,410,612 shares of the medical equipment provider’s stock valued at $357,618,000 after buying an additional 130,470 shares during the period. Mercer Global Advisors Inc. ADV lifted its stake in shares of STERIS by 39.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 20,066 shares of the medical equipment provider’s stock valued at $5,087,000 after buying an additional 5,644 shares during the period. Finally, EP Wealth Advisors LLC bought a new stake in shares of STERIS in the fourth quarter valued at about $720,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

STE has been the topic of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. UBS Group initiated coverage on shares of STERIS in a research report on Tuesday. They set a “buy” rating and a $275.00 target price for the company. KeyCorp decreased their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, STERIS has an average rating of “Moderate Buy” and an average target price of $277.25.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.